Wealthfront Advisers LLC Raises Stock Holdings in Merck & Co., Inc. $MRK

Wealthfront Advisers LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 18.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 210,569 shares of the company’s stock after purchasing an additional 33,127 shares during the quarter. Wealthfront Advisers LLC’s holdings in Merck & Co., Inc. were worth $17,673,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Dakota Community Bank & Trust NA grew its stake in shares of Merck & Co., Inc. by 3.4% in the 3rd quarter. Dakota Community Bank & Trust NA now owns 3,566 shares of the company’s stock worth $299,000 after buying an additional 116 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its holdings in shares of Merck & Co., Inc. by 3.6% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 3,402 shares of the company’s stock valued at $286,000 after acquiring an additional 119 shares during the last quarter. Investors Research Corp grew its position in Merck & Co., Inc. by 1.3% in the third quarter. Investors Research Corp now owns 9,325 shares of the company’s stock worth $783,000 after acquiring an additional 120 shares in the last quarter. Trust Point Inc. raised its position in Merck & Co., Inc. by 0.8% during the third quarter. Trust Point Inc. now owns 14,834 shares of the company’s stock valued at $1,245,000 after purchasing an additional 120 shares during the period. Finally, Nicolet Bankshares Inc. raised its position in Merck & Co., Inc. by 2.0% during the second quarter. Nicolet Bankshares Inc. now owns 6,169 shares of the company’s stock valued at $488,000 after purchasing an additional 121 shares during the period. Institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, CMO Chirfi Guindo sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares in the company, valued at approximately $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at approximately $52,362,780.08. This trade represents a 9.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 320,176 shares of company stock worth $38,281,735. 0.09% of the stock is owned by company insiders.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $117.12 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.66 and a debt-to-equity ratio of 0.77. The stock’s fifty day moving average is $107.22 and its two-hundred day moving average is $93.75. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $122.66. The company has a market capitalization of $290.69 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 2.20 and a beta of 0.28.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 45.22% and a net margin of 28.08%.The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is 46.70%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Short interest fell ~14.6% in January to ~28.7M shares (≈1.2% of float), lowering short‑pressure and reducing the odds of a short‑squeeze‑driven reversal. (Data: Jan. 30 short interest)
• Positive Sentiment: Bullish research argues Merck’s recent rally isn’t excess — analysts highlight extended Keytruda exclusivity, QLEX migration and pipeline/BD upside as durable revenue drivers. This supports longer‑term upside expectations. Merck: A Buy For 2026, But The Clock Is Still Ticking
• Positive Sentiment: Merck entered a strategic collaboration with Calla Lily Clinical Care to advance an intravaginal drug‑delivery platform (Callavid®), expanding non‑oncology device/partnered opportunities that could augment future topline or BD interest. Calla Lily Collaboration
• Neutral Sentiment: Merck reaffirmed solid fundamentals: recent quarter beat estimates, announced a $0.85 quarterly dividend (ex‑dividend March 16) and provided FY‑2026 EPS guidance. These support income/long‑term holders but may be largely priced in near term.
• Negative Sentiment: Large, high‑visibility insider sale: EVP Jennifer Zachary sold 121,573 shares (~$14.5M) at ≈$119.15 and materially reduced her stake — a prominent executive sale that can spook short‑term traders. Form 4 — Jennifer Zachary
• Negative Sentiment: Additional insider sales: CMO Chirfi Guindo sold 10,000 shares (~$1.18M) and other senior executives (including the CFO and another EVP) disclosed multi‑million dollar sales, amplifying negative sentiment from leadership selling. Form 4 — Chirfi Guindo CFO Sale Coverage
• Negative Sentiment: Some market commentary and at least one downgrade flag a near‑term balancing act — caution about valuation after a strong run and nearer‑term catalysts keeps trading volatility elevated. Balancing Act Article

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research note on Thursday, December 4th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Cantor Fitzgerald lifted their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Eight equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $120.93.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.